Interleukin 22 polymorphisms and papillary thyroid cancer

Journal of Endocrinological Investigation

Volumn 36, Issue 8, 2013, Pages 584-587

  Eun, Y G ^a   Shin, I H ^a   Lee, Y C ^a   Shin, S Y ^a   Kim, S K ^a   Chung, J H ^a   Kwon, K H ^b  

^a Kyung Hee University Hospital   (South Korea)

^b Hallym University   (South Korea)

Author keywords

Gene; Interleukin 22; Papillary thyroid cancer; Single nucleotide polymorphism

Indexed keywords

INTERLEUKIN 22;

ADULT; ARTICLE; CANCER GENETICS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID PAPILLARY CARCINOMA;

ADULT; AGED; CARCINOMA; FEMALE; GENE FREQUENCY; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN; RISK FACTORS; THYROID NEOPLASMS;

EID: 84885638583     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8879     Document Type: Article

References (22)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295: 2164-7.
2. Schlumberger M, Cailleux AF, Suarez HG, et al. Irradiation and second cancers. The thyroid as a case in point. C R Acad Sci III. 1999, 322: 205-13.
3. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995, 141: 259-77.
4. Lund E, Galanti MR. Incidence of thyroid cancer in Scandinavia following fallout from atomic bomb testing: an analysis of birth cohorts. Cancer Causes Control 1999, 10: 181-7.
5. Baverstock K, Egloff B, Pinchera A, et al. Thyroid cancer after Chernobyl. Nature 1992, 359: 21-2.
6. Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical- pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003, 120: 71-7.
7. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63: 1454-7.
8. Fusco A, Chiappetta G, Hui P, et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol 2002, 160: 2157-67.
9. Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 2000, 164: 1814-9.
10. Aujla SJ, Kolls JK. IL-22: a critical mediator in mucosal host defense. J Mol Med 2009, 87: 451-4.
11. Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008, 14: 282-9.
12. Wolk K, Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006, 17: 367-80.
13. Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity 2004, 21: 241-54.
14. Thompson CL, Plummer SJ, Tucker TC, et al. Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control 2010, 21: 1165-70.
15. Rebai M, Kallel I, Charfeddine S, et al. Association of polymorphisms in estrogen and thyroid hormone receptors with thyroid cancer risk. J Recept Signal Transduct Res 2009, 29: 113-8.
16. Lin JC, Kuo WR, Chiang FY, et al. Glutathione peroxidase 3 gene polymorphisms and risk of differentiated thyroid cancer. Surgery 2009, 145: 508-13.
17. Eun YG, Shin IH, KimMJ, et al. Associations between promoter polymorphism -106A/G of interleukin-11 receptor alpha and papillary thyroid cancer in Korean population. Surgery 2012, 151: 323-9.
18. Eun YG, Hong IK, Kim SK, et al. A polymorphism (rs1801018, Thr7Thr) of BCL2 is associated with papillary thyroid cancer in Korean population. Clin Exp Otorhinolaryngol 2011, 4: 149-54.
19. Lejeune D, Dumoutier L, Constantinescu S, et al. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002, 277: 33676-82.
20. Sekikawa A, Fukui H, Suzuki K, et al. Involvement of the IL-22/REG I alpha axis in ulcerative colitis. Lab Invest 2010, 90: 496-505.
21. Hennig BJ, Frodsham AJ, Hellier S, et al. Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. Liver Int 2007, 27: 1134-43.
22. Endam LM, Bosse Y, Filali-Mouhim A, et al. Polymorphisms in the interleukin-22 receptor alpha-1 gene are associated with severe chronic rhinosinusitis. Otolaryngol Head Neck Surg 2009, 140: 741-7.